To The Moon

Novo Nordisk Q3: A Third Guidance Raise This Year, But Can It Protect Pricing? A Put Seller's Deep Dive, With the Strike Zone and the Trigger Written Wednesday 4 Nov, SGT, a few hours after Novo's 7:30 AM CET release. The US session hasn't opened yet. THE HEADLINE: A THIRD RAISE Novo's 2026 outlook has improved three times: - May: adjusted sales and operating profit expected to fall 4% to 12% at constant exchange rates - August: raised to a decline of 0% to 6% - Today: raised again to between -2% and +2% Management says the driver is "increased expectations for GLP-1 product sales". A year that looked like a steep decline now looks roughly flat. That's the real story. THE QUARTER (DKK) - Net sales: 79.2 billion, up 6% in kroner and 4% at constant exchange rates - Adjusted operating profit:

Hi there guys happy trading 

Absolutely no way - the fat reducing medications like Wegovic and the likes will always win out

$WORK Medical Technology Group, Ltd.(WOK)$ see ya all incoming price! 8.5$ ✊🏻✨✨‼️‼️🤏🤏🚨🚨🚨🚨

 ！。。。。！*。！3@HD6 ？

$Novo-Nordisk A/S(NVO)$   Its undervalued right now

$Ispire Technology Inc.(ISPR)$ $Ispire Technology (ISPR.US)$ Be Ready to climb just like WOK i posted yesterday.. RAMPAGE BULL RALLY

Hi how can i help you

Hims & Hers Q1 Showdown: Can the Novo Nordisk Partnership Shield HIMS From an FDA Compounding Ban? Hims & Hers ($HIMS) is set to report highly anticipated Q1 2026 earnings tomorrow after the closing bell, riding an explosive +37% monthly rally that completely defied the broader healthcare sector slump. With the FDA aggressively proposing to exclude key weight-loss molecules from its 503B compounding bulks list, retail bears are betting on a catastrophic revenue cliff. Meanwhile, Eli Lilly ($LLY) just surged 10% on a massive earnings beat, leaving traders wondering: is Hims about to follow Lilly to new highs, or are traders walking straight into a regulatory trap? Here is the data-driven breakdown of how the smart money is positioning for the print. 1️⃣ The FDA 503B Proposal & T

Hims & Hers:  The High Stakes Gamble for a Weight Loss Revolution  🌟🌟🌟The energy around $Hims & Hers Health Inc.(HIMS)$  right now is electric - a mix of raw excitement and hold your breath anxiety.  After watching $Eli Lilly(LLY)$  deliver a powerhouse earnings that sent its stock surging 10%, we are all asking the same question : Can HIMS do it too? It feels like we are standing on the edge of a fundamental shift.  While Lilly owns the crown of the innovator, Hims & Hers is playing a more emotive game - the game of access.  HIMS is betting that the miracle of weight loss should not be just for tho

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

Novo Nordisk Q3: A Third Guidance Raise This Year, But Can It Protect Pricing? A Put Seller's Deep Dive, With the Strike Zone and the Trigger Written Wednesday 4 Nov, SGT, a few hours after Novo's 7:30 AM CET release. The US session hasn't opened yet. THE HEADLINE: A THIRD RAISE Novo's 2026 outlook has improved three times: - May: adjusted sales and operating profit expected to fall 4% to 12% at constant exchange rates - August: raised to a decline of 0% to 6% - Today: raised again to between -2% and +2% Management says the driver is "increased expectations for GLP-1 product sales". A year that looked like a steep decline now looks roughly flat. That's the real story. THE QUARTER (DKK) - Net sales: 79.2 billion, up 6% in kroner and 4% at constant exchange rates - Adjusted operating profit:

Hims & Hers:  The High Stakes Gamble for a Weight Loss Revolution  🌟🌟🌟The energy around $Hims & Hers Health Inc.(HIMS)$  right now is electric - a mix of raw excitement and hold your breath anxiety.  After watching $Eli Lilly(LLY)$  deliver a powerhouse earnings that sent its stock surging 10%, we are all asking the same question : Can HIMS do it too? It feels like we are standing on the edge of a fundamental shift.  While Lilly owns the crown of the innovator, Hims & Hers is playing a more emotive game - the game of access.  HIMS is betting that the miracle of weight loss should not be just for tho

Hims & Hers Q1 Showdown: Can the Novo Nordisk Partnership Shield HIMS From an FDA Compounding Ban? Hims & Hers ($HIMS) is set to report highly anticipated Q1 2026 earnings tomorrow after the closing bell, riding an explosive +37% monthly rally that completely defied the broader healthcare sector slump. With the FDA aggressively proposing to exclude key weight-loss molecules from its 503B compounding bulks list, retail bears are betting on a catastrophic revenue cliff. Meanwhile, Eli Lilly ($LLY) just surged 10% on a massive earnings beat, leaving traders wondering: is Hims about to follow Lilly to new highs, or are traders walking straight into a regulatory trap? Here is the data-driven breakdown of how the smart money is positioning for the print. 1️⃣ The FDA 503B Proposal & T

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

Hi there guys happy trading 

$Ispire Technology Inc.(ISPR)$ $Ispire Technology (ISPR.US)$ Be Ready to climb just like WOK i posted yesterday.. RAMPAGE BULL RALLY

 ！。。。。！*。！3@HD6 ？

$WORK Medical Technology Group, Ltd.(WOK)$ see ya all incoming price! 8.5$ ✊🏻✨✨‼️‼️🤏🤏🚨🚨🚨🚨

Absolutely no way - the fat reducing medications like Wegovic and the likes will always win out

$Novo-Nordisk A/S(NVO)$   Its undervalued right now

Hi how can i help you